All things lie dormant in winter, and spring begins anew with the start of a new year. As the New Year's Day of 2025 approached, a delegation led by Liu Qunying, former deputy director of the Standing Committee of the Fujian Provincial People's Congress and director of the Working Committee on Caring for the Next Generation of Fujian Province, came to conduct research at Sino Universal Pharma (hereinafter referred to as “SUP”). Zhang Zhong, deputy director of the Working Committee on Caring for the Next Generation of Fujian Province and director of the Enterprise Committee, along with members of the Enterprise Committee of the Working Committee on Caring for the Next Generation of Fujian Province, accompanied them on the research.

The management team of SUP and Director Liu Qunying's group got together, exchanged greetings amicably in a warm scene. Mr. Li Wang, the chairman of SUP, delivered a report on "The Enterprise Development of SUP", which concisely outlined the enterprise's history and its five-year strategic plan in terms of ecology, platform, milestones, social welfare and future prospects. Both sides also discussed SUP's industrial chain layout, internationalization progress, corporate culture and organizational building.

After hearing the work report, Director Liu Qunying highly praised SUP’s high-quality development. She noted that, under the drug review and approval reform policy, the "import + self-developed" dual-drive product strategy of SUP could boost the industry and meet more public health demands. She also mentioned that the Enterprise Committee of the Provincial Working Committee for the Care of the Next Generation will tighten cooperation with SUP, contribute to the growth of its young staff, jointly conduct public welfare activities for public health, and enhance people's well-being, fulfillment, and security.